David Rizzo, DO
Family Medicine · Sarasota, FLNPI 1447267208
Payments from drug & device makers
Across 147 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$582
- Pfizer$252
- AbbVie$237
- Exact Sciences$116
- Lilly USA, LLC$113
- Takeda Pharmaceuticals U.S.A., Inc.$105
- plus $824 from 20 others
What the payments were for
- Consulting fees$100%
- Food & beverage$2,218100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 49 | $582 |
| Pfizer | 14 | $252 |
| AbbVie(2 entities) | 20 | $237 |
| Exact Sciences | 5 | $116 |
| Lilly USA, LLC | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $105 |
| GSK | 5 | $100 |
| AstraZeneca | 7 | $95 |
| Kowa Pharmaceuticals America, Inc. | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $55 |
| Amgen(2 entities) | 3 | $53 |
| Biohaven Pharmaceuticals, Inc. | 2 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $39 |
| Bayer | 2 | $37 |
| Sanofi | 1 | $37 |
| Merck | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Kvk-tech, Inc. | 4 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
How this compares
$2,228 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 442 | $149,517 |
| MounjaroTirzepatide | 30 | $31,078 |
| OzempicSemaglutide | 27 | $28,110 |
| JanuviaSitagliptin Phosphate | 68 | $26,708 |
| JardianceEmpagliflozin | 50 | $26,247 |
| XareltoRivaroxaban | 83 | $24,063 |
| MyrbetriqMirabegron | 29 | $18,986 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $18,247 |
| XifaxanRifaximin | 13 | $15,986 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 85 | $14,474 |
| FarxigaDapagliflozin Propanediol | 45 | $13,081 |
| EntrestoSacubitril/Valsartan | 26 | $11,920 |
| Potassium Chloride | 388 | $11,841 |
| Gabapentin | 458 | $11,394 |
| Atorvastatin Calcium | 675 | $10,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $252 | $149,517442 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta, Symbicort | $95 | $43,034107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $113 | $41,83243 claims |
| Novo NordiskOzempic | $23 | $28,11027 claims |
| MerckJanuvia | $33 | $26,70868 claims |
| Johnson & JohnsonXarelto | $19 | $24,06383 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $39 | $15,98613 claims |
| NovartisEntresto | $582 | $11,92026 claims |
| AbbVieCreon | $237 | $7,66518 claims |
| GSKBreo Ellipta | $100 | $5,89016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Sarasota
- Niaz AusafSarasota$3.8M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.